

Index

- Absorbed doses, 121, 122, 255, 256, 263–266, 270–271, 273–275
Absorbed fractions (AFs), 255, 262
Acceptor, 166, 170
Activity dose, 109, 131
Activity meter, 61, 62
AD. *See* Alzheimer's disease
Adverse reactions, 119
Affinity, 111, 112
Afterglow, 162, 164, 165, 167
Algebraic reconstruction, 209, 216
Alkali halides, 163–165
Alzheimer's disease (AD), 105, 106, 110–114, 116, 130–132
Amyloid β , 105, 110–114, 130, 131
Analog Monte Carlo, 39, 40, 44
Analytical methods, 209, 211, 214, 215, 220
Anatomical standardization, 129
Angular flux, 36, 37, 48
Animal models, 116
Application-specific integrated circuit (ASIC), 156
A-priori model identifiability, 244–247
ASIC. *See* Application-specific integrated circuit
Attenuation correction, 61, 64–69
Auger emitters, 76, 78, 90
Authorizations, 94–96
Autoradiography, 112–114
Avalanche photodiodes, 171
- Background correction, 236
Barkas corrections, 23
Bethe–Bloch, 16, 19, 20, 23, 24
Biased Monte Carlo, 45
Biokinetics, 231–252
Biomedical physics, 7–10
Boltzmann equation, 37–38, 40, 48
Born approximation, 16, 18, 23, 31
Boundary crossing estimation, 54
Bragg additivity, 22–24
Bragg peak, 23, 25, 33
Breath tests, 75, 76
- Carrier free, 80, 81
Central limit theorem, 39, 55
Chelator, 79, 87–90
Chemistry, manufacturing, and control (CMC), 107
CI. *See* Confidence interval
Clinical development, 105, 108, 109, 118–134
CMC. *See* Chemistry, manufacturing, and control
Coincidence, 193, 197, 201, 203
Cold kits, 72, 80
Columns, 257
Compartmental models, 240–244, 249
Compartment models, 127
Compound-related safety, 119–120
Compton camera, 140, 141, 152–157
Compton scattering (CS), 141, 142, 144–147, 153, 155
Computed tomography (CT), 61, 66–69, 139, 140, 149, 164, 165
Condensed history, 36, 38, 46
Conductance, 168, 170
Confidence interval (CI), 134
Conjugate view counting, 123
Conjugate view method, 237, 251
Continuous processes, 46–47
Continuous slowing down approximation (CSDA), 25, 26
Conversion, 159–162
Cortical bone, 257, 258
Coulomb scattering, 15, 21, 29–31
Cross fire, 76

- CSDA. *See* Continuous slowing down approximation
- CT. *See* Computed tomography
- Cumulated activity, 114, 121, 122, 125, 126
- Cyclotron, 72, 75, 77, 78, 81–84, 96
- Data acquisition, 197, 202–204
- Dead time, 149, 151–152
- Decay time, 160, 162, 165, 167
- Deexcitation processes, 159, 160
- Dementia, 105–107, 110–114, 129, 130
- Dementia with Lewy bodies (DLB), 111
- Density, 160, 163, 165, 167
- Density correction, 19
- Density effect, 19, 21
- Depletion region, 171
- Detector design, 202
- Detector development, 174–182
- Detectors, 37, 38, 47–49, 53–56
- Deterministic effects, 120, 121
- Diagnostic radionuclides, 75
- Discrete processes, 46
- DLB. *See* Dementia with Lewy bodies
- Donor, 166, 170
- Doppler broadening, 155
- 8-ray, 26–28
- Dry distillation, 85
- ED. *See* Effective dose
- Effective atomic number, 163–165
- Effective dose (ED), 118, 119, 122, 126
- Efficiency, 161, 164, 165, 169
- Electronic collimation, 141
- Electron interactions, 142–147
- Emission spectrum, 162–165
- Endosteal tissues, 257
- Energy losses, 15–21, 23, 25–29, 31, 33
- Energy loss fluctuations, 23, 26, 29
- Energy transfer, 15–17, 20, 27, 76, 145, 161
- Equilibrium dissociation constant K_d , 112, 129
- Equivalent dose H , 122
- Estimator, 39, 48, 53–55
- European Medicines Agency (EMA), 95–97
- Events, 40, 43, 44, 46–47, 56
- Excretion pathway, 88, 90
- [¹⁸F]-Fluoro-deoxy-glucose (FDG), 72, 87, 88, 106, 110, 119, 129, 263, 266, 273
- Figure of merit, 47–48, 50
- Filtered backprojection, 199, 213, 215
- Fluence, 37
- Four-momentum transfer, 16
- Frontotemporal dementia (FTD), 111, 113, 114
- FTD. *See* Frontotemporal dementia
- Gamma camera, 63–65, 139, 141, 152–154, 164
- Gamma-ray, 141, 142, 153
- GCP. *See* Good clinical practice
- Good clinical practice (GCP), 118–119
- Good manufacturing practice, 93–94
- HAMAs. *See* Human antimouse antibodies
- High-throughput screening (HTS), 112
- Historical timeline of nuclear medicine, 3
- History, 35, 36, 43, 46, 50, 51
- HTS. *See* High-throughput screening
- Human antimouse antibodies (HAMAs), 120
- Hybrid imaging, 61
- Hygroscopicity, 163, 167
- ICH. *See* International Conference on Harmonization
- ICRP. *See* International Commission on Radiological Protection
- ¹²³I-iodide, 270
- Image intensifier-based, 164
- Imaging windows, 109
- Immunohistochemistry, 113, 114
- Importance biasing, 49
- Importance sampling, 52
- Inelastic atomic form factor, 30
- Integration, 37, 39–43, 54
- Integration efficiency, 40
- Internal dose, 231–233
- International Commission on Radiological Protection (ICRP), 122, 232, 233, 246
- International Conference on Harmonization (ICH), 118
- Interorgan distances, 256, 260, 269, 270, 272, 274
- In vivo* generators, 79
- Ion exchange, 80, 85
- Ionizing radiation, 139–157
- Iterative reconstruction, 209, 213–217, 224, 227
- Kinetic modeling, 127, 128

- Labelling, 72–74, 81, 86–90, 93, 95
Landau distribution, 28, 29
Landau fluctuations, 27–29
Lead compound, 107
Leading particle biasing (LPB), 50–51
Linear energy transfer (LET), 76, 87
Linearity, 160, 161
Linear nonthreshold (LNT) model, 121
Line of response (LOR), 194, 196, 197
Low-dose CT, 67
Luminescence, 160, 162
Luminescent centre, 159–161
- Macroscopic cross section, 37
Macroscopic Monte Carlo, 44
Magnifying probe, 193–198
Manufacturing, 85–91, 93–95
 μ -map, 65, 66
Market authorisation, 95–97
Marketing, 93–95
Marrow cellularity, 258
Maximum likelihood expectation
 maximisation, 226, 228
Mean, 35, 37–40, 45, 48, 51–53, 55
Mean excitation energy, 18
Mean ionization energy, 22
Measurement statistics, 139, 147–149
Medical imaging, 139–157
Medical Internal Radiation Dose (MIRD)
 committee, 121, 122, 232, 233, 242
Medical needs, 105–107, 110
Medullary cavity, 258
Mesh (or binning) estimator, 47, 54
Metabolism, 106, 108, 110, 126, 127
Microdosing, 108
MIRD. *See* Medical internal radiation dose
Modeling of PET tracer kinetics, 115, 127–129
Module, 204–206
Molecular imaging, 7–10, 105–107, 109–112
Molière theory, 30
Möller and Bhabha scattering, 21
 $^{99}\text{Mo}/^{99\text{m}}\text{Tc}$ generator, 72, 80, 81, 97
Monte Carlo, 23, 28, 29
Monte Carlo code, 28, 31
Monte Carlo method, 35, 36, 38–40
Multiple scattering, 29, 31, 33
- Nanoparticles, 73
No carrier added, 80
Noise advantage, 201
Nonanalog absorption, 51
Nuclear medicine, 61–69
- Nucleus charge form factor, 29
Nucleus elastic atomic form factor, 29
- Organ cross fire, 256, 260, 265, 267, 272–274
Organ identification numbers, 257
Organ self-absorption, 256, 259, 267, 272, 274
- Packaging, 197, 205–206
Packaging factor, 205
Particle transport, 35–37, 42–46
Patient information, 118
Pencil beam, 37
Peptide, 73, 81, 86–90
PET. *See* Positron emission tomography
PET/CT, 61, 68–69
Phage display technique, 112
Pharmacokinetics (PK), 108, 126
Phase I studies, 108
Phase II studies, 108–109
Phase III studies, 109
Phase space, 36–38, 40, 44, 45, 48–50, 54
Photoconductive, 169, 170
Photodiode, 164, 170, 171
Photoelectric effect, 142–146, 155
Photon interactions, 142–147, 149, 153
Photovoltaic, 170
PK. *See* Pharmacokinetics
p-n junction, 170, 171
Positron emission tomography (PET), 61, 66,
 68–69, 72, 74, 75, 78, 81, 88, 91,
 139–142, 147, 165, 166, 233–236,
 251, 252
Pretargeting, 73
Probability distribution function, 40, 47, 48
Probe resolutions, 196, 197, 206
Production thresholds, 47
Proof of mechanism (PoM) study, 108
Pseudorandom, 40–41
Pulse height estimator, 54
- Quality assurance (QA), 56, 91, 93–94
Quality control, 91–93
Quantum efficiency, 161, 164, 169
- Radiation detection, 139–157
Radiation dose, 114, 115, 119, 121, 126
Radiation dosimetry, 108, 114–115, 121,
 123, 124
Radiation sources, 61, 68
Radioiodination, 88

- Radiolabelling, 71, 73, 74, 79, 85, 87–90, 96
 Radiolysis, 87, 90
 Radionuclide
 availability, 80–81, 96–97
 flood sources, 63, 64
 generators, 72, 75, 77, 80–86, 97
 line sources, 63–65
 planar sources, 63
 point sources, 63
 Radiopharmaceuticals, 71–97, 105–134
 Radon transform, 214
 Random sampling, 40–43
 Range, 23–26
 Rate constants, 127–129
 Readout electronics, 197, 198, 202–204
 Receptors, 109, 110, 112, 127, 129, 131
 Reciprocity, 269
 Reciprocity principle, 274
 Recombination processes, 160
 Reconstruction, 209–228
 Red bone marrow, 258
 Reference female, 257–259, 263–265, 271, 274
 Reference male, 257–259, 263–265, 271
 Rejection technique, 42–43
 Research reactors, 71, 73, 96, 97
 Resistance, 163, 168, 170
 Restricted energy loss, 20–21
 Role of radiation physics in nuclear medicine, 3–5
 Rows, 257
 Russian roulette (RR), 49
- Safety pharmacology toxicology, 108
 Sampling from a biased distribution, 52–53
 Sampling from a discrete distribution, 41, 43
 Sampling from a generic continuous distribution, 41–42
 Scaling, 114, 115
 Scintillation optical ceramics, 165
 Scintillators, 144, 146, 151, 153, 159–171
 Score, 47, 49–51, 53, 54, 56
 Self-absorption, 162
 Semiconductors, 144, 146, 159–171
 Sensitivity, 106, 109, 111, 133, 134
 Shell corrections, 19, 20, 22
 Signal formation, 203
 Signal formation time, 203, 204
 Signal processing, 149–151, 156
 Silicon, 196, 198, 202–204
 Silicon pad, 194, 198, 202, 206
 Silicon pad detectors, 198, 202, 205
- Single-photon emission computed tomography (SPECT), 64–69, 72, 74, 75, 78, 81, 139–142, 233–236, 249, 251
 Skeleton, 257, 258, 268, 273, 274
 Slices, 257, 267
 Small-animal imaging systems, 115
 Solvent extraction, 85
 Somatostatin receptors, 73, 86, 89
 SoT. *See* Standard of truth
 Source organ, 255, 262–264, 266–267, 270–275
 Sources, 37, 38, 48
 Spatial resolution, 75
 Specific absorbed fractions (SAFs), 255–275
 Specific activity, 79–82, 84, 85, 87, 92, 96
 Specificity, 109, 111, 112, 133, 134
 SPECT. *See* Single-photon emission computed tomography
 SPECT/CT, 61, 66–69
 Spectral responsivity, 169–171
 SPM. *See* Statistical parametric mapping
 Stack, 43
 Stack of modules, 204
 Standardized uptake value ratios (SUVRs), 131, 132
 Standardized uptake values (SUVs), 124, 131, 132
 Standard of truth (SoT), 131–133
 Statistical errors, 54–56
 Statistical parametric mapping (SPM), 129
 Statistical weight, 48
 Stochastic effects, 120, 121
 Stopping power, 15, 19, 23–25
 Surface splitting, 49
 Surrogate standard, 132
 SUVRs. *See* Standardized uptake value ratios
 SUVs. *See* Standardized uptake values
 S values, 115, 122, 255, 265, 274
 Systematic errors, 54, 56
- TACs. *See* Time activity curves
 Tally, 53, 55
 Target, 71, 73, 74, 76, 78–82, 84–87, 89–91, 96, 97
 Targeting, 109, 110, 112–114, 116, 117, 130, 131
 Target organ, 255, 256, 269, 274
 Target region, 255, 256, 259, 261, 262
^{99m}Tc-pertechnetate, 270, 273
 Therapeutic radionuclides, 76–78
 Time activity curves (TACs), 115, 125–128, 232–239
 Time walk, 203, 204

- Timing, 203–204
- Trabecular bone, 257
- Tracer, 71, 74, 86–88, 91
- Track length estimator, 54
- Transfer rates, 242
- Transport, 159–162
- Transport thresholds, 47
- Trends, innovation, 173–187

- Variance, 39, 40, 45, 47, 48, 50, 55
- Variance reduction, 35, 45, 47–49, 56
- Vascular dementia (VaD), 111
- Vavilov's distribution, 29
- Visual analysis of images, 129–131
- Voxel, 45, 255–275

- Voxel-based statistical analysis, 129
- Voxel phantoms, 255–275

- Weight window, 49–51
- Whole-body imaging protocols, 123–124
- WMA. *See* World Medical Association
- World Medical Association (WMA), 118

- Xenografts, 115–117
- X-ray, 61–69, 139–143, 147–149

- Yellow bone marrow, 257, 258